LUND, SWEDEN--(Marketwire - June 7, 2007) - Jerusalem, Israel and Lund, Sweden, June 7,
2007 - Teva
Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech AB
(OMX NORDIC: ACTI) today announced that the companies are initiating
a clinical Phase III program for laquinimod, a novel once-daily,
orally administered immunomodulatory compound for the treatment of
relapsing multiple sclerosis (RMS). The studies will now begin
following the successful conclusion of a second phase II study and
the outcome of discussions with the U.S. Food and Drug Administration
(FDA) and the European Medicines Agency (EMEA).